COMMENTARY   Open Access    

Pushing the boundary of cancer diagnostics through microfluidic technologies

More Information
  • Corresponding author: hangheng.wong@gwu.edu
  • 加载中
  • [1] Murphy, J.B., and Sturm, E. (1925). Primary lung tumors in mice following the cutaneous application of coal tar. J. Exp. Med. 42, 693−700.

    View in Article CrossRef Google Scholar

    [2] Nielsen, T.O., Parker, J.S., Leung, S., et al. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer. Clin. Cancer Res. 16, 5222.

    View in Article CrossRef Google Scholar

    [3] Office of Science and Engineering Laboratories. (2021). Microfluidics program: research on microfluidics-based medical devices. US Food and Drug Administration.

    View in Article Google Scholar

    [4] Jonasson, O. (1958). The viability of circulating cancer cells in experimental cancer. Surg. Forum. 9, 577−580.

    View in Article Google Scholar

    [5] Kalluri, R., and McAndrews, K.M. (2023). The role of extracellular vesicles in cancer. Cell. 186, 1610−1626.

    View in Article CrossRef Google Scholar

  • Cite this article:

    Wong AH. (2023). Pushing the boundary of cancer diagnostics through microfluidic technologies. The Innovation Medicine 1(1), 100005. https://doi.org/10.59717/j.xinn-med.2023.100005
    Wong AH. (2023). Pushing the boundary of cancer diagnostics through microfluidic technologies. The Innovation Medicine 1(1), 100005. https://doi.org/10.59717/j.xinn-med.2023.100005

Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(2138) PDF downloads(342) Cited by(0)

Relative Articles

Article Contents

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint